PH30685A - Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Info

Publication number
PH30685A
PH30685A PH48985A PH48985A PH30685A PH 30685 A PH30685 A PH 30685A PH 48985 A PH48985 A PH 48985A PH 48985 A PH48985 A PH 48985A PH 30685 A PH30685 A PH 30685A
Authority
PH
Philippines
Prior art keywords
mofetil
mycrophenolate
crystalline anhydrous
intravenous formulation
crystalline
Prior art date
Application number
PH48985A
Other languages
English (en)
Inventor
Roger C Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Andrew R Miksztal
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of PH30685A publication Critical patent/PH30685A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PH48985A 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof PH30685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (1)

Publication Number Publication Date
PH30685A true PH30685A (en) 1997-09-16

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
PH48985A PH30685A (en) 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Country Status (31)

Country Link
US (2) US5543408A (pl)
EP (1) EP0724581B1 (pl)
JP (1) JP3411038B2 (pl)
KR (1) KR100349772B1 (pl)
CN (1) CN1060770C (pl)
AT (1) ATE173475T1 (pl)
AU (1) AU677435B2 (pl)
BR (1) BR9407469A (pl)
CA (1) CA2171836C (pl)
CZ (1) CZ292423B6 (pl)
DE (1) DE69414720T2 (pl)
DK (1) DK0724581T3 (pl)
ES (1) ES2123831T3 (pl)
FI (1) FI119639B (pl)
HU (1) HU217300B (pl)
IL (1) IL110970A (pl)
LT (1) LT4052B (pl)
LV (1) LV11326B (pl)
MX (1) MXPA94007099A (pl)
NO (1) NO314727B1 (pl)
NZ (1) NZ273801A (pl)
PH (1) PH30685A (pl)
PL (1) PL178522B1 (pl)
RO (2) RO118427B1 (pl)
RU (1) RU2132849C1 (pl)
SG (1) SG55006A1 (pl)
SI (1) SI9420052B (pl)
TW (1) TW370527B (pl)
UA (1) UA49797C2 (pl)
WO (1) WO1995007902A1 (pl)
ZA (1) ZA947088B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (pl) 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
DE602004015310D1 (de) * 2003-09-11 2008-09-04 Sandoz Ag Verfahren zur herstellung von mycophenolatmofetil
MXPA06005659A (es) * 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
EP1740563A2 (en) * 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
PL313480A1 (en) 1996-07-08
ZA947088B (en) 1996-03-14
SI9420052B (sl) 2004-02-29
CA2171836A1 (en) 1995-03-23
HU217300B (hu) 1999-12-28
KR100349772B1 (ko) 2002-12-28
SG55006A1 (en) 1998-12-21
RO118427B1 (ro) 2003-05-30
IL110970A0 (en) 1994-11-28
CN1060770C (zh) 2001-01-17
FI961169A0 (fi) 1996-03-13
EP0724581B1 (en) 1998-11-18
DE69414720D1 (de) 1998-12-24
NO314727B1 (no) 2003-05-12
HUT75119A (en) 1997-04-28
NZ273801A (en) 1997-10-24
US5543408A (en) 1996-08-06
LV11326A (lv) 1996-06-20
DE69414720T2 (de) 1999-04-08
RO118075B1 (ro) 2003-01-30
CN1131420A (zh) 1996-09-18
LT96028A (en) 1996-08-26
RU2132849C1 (ru) 1999-07-10
LT4052B (en) 1996-10-25
JPH09502721A (ja) 1997-03-18
FI119639B (fi) 2009-01-30
CZ78896A3 (en) 1996-10-16
LV11326B (en) 1996-10-20
US5545637A (en) 1996-08-13
ATE173475T1 (de) 1998-12-15
CA2171836C (en) 2006-11-14
NO961075L (no) 1996-03-15
NO961075D0 (no) 1996-03-15
CZ292423B6 (cs) 2003-09-17
UA49797C2 (uk) 2002-10-15
DK0724581T3 (da) 1999-08-02
IL110970A (en) 1999-01-26
HK1012624A1 (en) 1999-08-06
JP3411038B2 (ja) 2003-05-26
BR9407469A (pt) 1996-11-12
EP0724581A1 (en) 1996-08-07
PL178522B1 (pl) 2000-05-31
AU7723894A (en) 1995-04-03
ES2123831T3 (es) 1999-01-16
HU9600652D0 (en) 1996-05-28
FI961169L (fi) 1996-03-13
TW370527B (en) 1999-09-21
SI9420052A (en) 1996-12-31
WO1995007902A1 (en) 1995-03-23
AU677435B2 (en) 1997-04-24
MXPA94007099A (es) 2004-01-23

Similar Documents

Publication Publication Date Title
ZA947088B (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
IL111365A0 (en) (r)-5-carbamoyl -8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1- benzopyrans
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MY100359A (en) External pharmaceutical composition.
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en) Antitumor Agents
HUT50345A (en) Process for production of cefem-derivatives and their intermediers
TW252979B (pl)
CA2063273A1 (en) Surfactant compositions and methods
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
MX9600165A (es) 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
EP0733364A4 (en) MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM
HUT66204A (en) Phytoactive compositions containing n-phosphonomethyl-clycine monoammonium salts as active ingredients and process for producing the compositions and the active ingredients